Tucker 2003.

Methods	DESIGN Description: random‐assignment, placebo‐controlled, parallel arm, flexible‐dose, double‐blind, single centre, 1‐2 week taper at end BLINDING Participants: Unclear Assessors: Unclear Administrators: Unclear ALLOCATION CONCEALMENT Method: Unclear RANDOMISATION Method: Unclear
Participants	SAMPLE Description: 59 DSM‐IV PTSD, mean age: 38.5 years, 72% (42/58) female, 3% (2/58) combat related, 78% (45/58) major depression, baseline severity on CAPS: citalopramine (91), sertraline (83.9) and placebo (94.2) SCREENING Primary diagnosis: SCID‐IV, CAPS‐I >=50 Comorbidity: Unclear
Interventions	Description: citalopram 20 mg/d ‐ 50 mg/d (final avg: 36.2 mg/d)) versus sertraline 50 mg/d ‐ 200 mg/d (final avg: 134.1mg/d)) versus placebo x 10 weeks
Outcomes	Primary outcomes: CAPS Secondary outcomes: IES (revised), BDI (revised) Data estimation: LOCF (2 post‐baseline assessment)
Notes	INDUSTRY SUPPORT Industry funded: Yes Medication provided by industry: Unclear Any of the authors work for industry: Yes ADDITIONAL INFORMATION Drop‐out rates: +‐20% (5/58) on citalopramine, +‐ 26% (6/23) on sertraline and +‐ 30% (3/10) on placebo Quality rating score: 26
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear